Zynerba Press Releases

26 Sep 19 Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

18 Sep 19 Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)

5 Sep 19 Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

5 Sep 19 New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

3 Sep 19 Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

29 Aug 19 Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium

6 Aug 19 Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders

6 Aug 19 Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

31 Jul 19 Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

1 Jul 19 Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes